Borowicz Kinga K, Piskorska Barbara, Kimber-Trojnar Zaneta, Małek Robert, Sobieszek Grzegorz, Czuczwar Stanisław J
Department of Pathophysiology, Medical University, Jaczewskiego 8, PL 20-090 Lublin, Poland.
Pol J Pharmacol. 2004 May-Jun;56(3):289-94.
Felbamate (2-phenyl-1,3-propanediol dicarbamate), a representative of novel antiepileptic drugs (AESs), proved to have broad-spectrum anticonvulsive activity. Particularly beneficial efficacy was found against partial seizures and Lennox-Gastaut syndrome. Therefore, felbamate started to be indicated not only as an adjunctive antiepileptic drug but also in monotherapy. Unfortunately, it was also evidenced that the drug may induce aplastic anemia or hepatic failure. The former complication was frequently described in patients with previously diagnosed hematopoetic disturbances. Thirty-four cases of well-documented bone marrow suppression, occurred fatal in thirteen cases. Subsequently, felbamate's usage was essentially restricted and at present felbamate is not a first-line AED. However, excluding anemia-prone individuals, new possibilities may open for felbamate position in add-on therapy of drug-resistant epilepsy. Experimental studies provide a good theoretical basis for this kind of treatment.
非氨酯（2-苯基-1,3-丙二醇二氨基甲酸酯）是新型抗癫痫药物（AESs）的代表，已被证明具有广谱抗惊厥活性。尤其在治疗部分性癫痫发作和伦诺克斯-加斯东综合征方面疗效显著。因此，非氨酯开始不仅被用作辅助抗癫痫药物，也用于单药治疗。不幸的是，也有证据表明该药物可能会诱发再生障碍性贫血或肝衰竭。前一种并发症在先前诊断有造血功能障碍的患者中经常出现。有34例记录充分的骨髓抑制病例，其中13例死亡。随后，非氨酯的使用受到了严格限制，目前它已不是一线抗癫痫药物。然而，排除易患贫血的个体，非氨酯在难治性癫痫的附加治疗中可能会有新的应用前景。实验研究为这种治疗提供了良好的理论基础。
